Fortress Biotech Swings to Q3 2026 Net Loss of $8.25 Million

PUBT · 2d ago
Fortress Biotech Swings to Q3 2026 Net Loss of $8.25 Million
  • Fortress Biotech swung to a third-quarter 2026 net loss attributable to common stockholders of $7.85 million from a year-earlier profit.
  • Net revenue rose approximately 9% year over year to $19.2 million.
  • Cash and cash equivalents climbed 92% from December 31, 2025, to $152.2 million at September 30, 2026.
  • September repayment of the remaining $15 million under the Oaktree credit facility left no outstanding debt at the parent level.
  • A subsidiary licensed IBS-D treatment FB-607, currently in Phase 2 testing, with top-line data expected in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130800PRIMZONEFULLFEED9876982) on November 13, 2026, and is solely responsible for the information contained therein.